Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
28,000
Employees28,000
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
28,000
Employees28,000

AMGN Key Statistics

Market cap
180.69B
Market cap180.69B
Price-Earnings ratio
25.62
Price-Earnings ratio25.62
Dividend yield
2.87%
Dividend yield2.87%
Average volume
3.84M
Average volume3.84M
High today
$333.67
High today$333.67
Low today
$327.70
Low today$327.70
Open price
$328.09
Open price$328.09
Volume
1.54M
Volume1.54M
52 Week high
$346.38
52 Week high$346.38
52 Week low
$257.05
52 Week low$257.05

Stock Snapshot

Amgen(AMGN) stock is priced at $331.49, giving the company a market capitalization of 180.69B. It carries a P/E multiple of 25.62 and pays a dividend yield of 2.9%.

As of 2025-12-23, Amgen(AMGN) stock has fluctuated between $327.70 and $333.67. The current price stands at $331.49, placing the stock +1.2% above today's low and -0.7% off the high.

Amgen(AMGN) shares are trading with a volume of 1.54M, against a daily average of 3.84M.

In the last year, Amgen(AMGN) shares hit a 52-week high of $346.38 and a 52-week low of $257.05.

In the last year, Amgen(AMGN) shares hit a 52-week high of $346.38 and a 52-week low of $257.05.

AMGN News

Simply Wall St 16h
Is There Still Value in Amgen After Its Strong 2025 Share Price Run?

Wondering if Amgen’s share price already reflects the upside, or if there is still value on the table? You are not alone, and this article is going to tackle th...

Is There Still Value in Amgen After Its Strong 2025 Share Price Run?
TipRanks 1d
Amgen’s Pediatric Inebilizumab Study Signals Long-Term Upside in Rare Autoimmune Disease

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data a...

TipRanks 1d
Amgen’s Long-Term Pediatric Psoriasis Study on Apremilast: Why the Latest Update Matters for Investors

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data a...

Analyst ratings

45%

of 31 ratings
Buy
45.2%
Hold
45.2%
Sell
9.7%

More AMGN News

TipRanks 3d
Schwab US Dividend Equity ETF Sees Inflows Amid Weekly Decline

Schwab US Dividend Equity ETF ( $SCHD ) has fallen by 1.08% in the past week. It has experienced a 5-day net inflow of $1.41 billion. This is due, in part, to...

TipRanks 4d
Amgen reaches pact with U.S. to reduce drug costs

Amgen (AMGN) announced it is taking action again with the U.S. government to lower medicine costs for American patients. The action satisfies the components out...

TipRanks 4d
Amgen Advances Olpasiran Heart Plaque Study, Highlighting a Growing Bet on Lipoprotein(a)

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data a...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.